Imovax Polio

Poliovirus (Inactivated) Type 1 (Mahoney), Type 2 (MEF‑1) and Type 3 (Saukett), the active ingredient in Imovax Polio, is a vaccine presented as a sterile injectable formulation for intramuscular or subcutaneous use. Produced under EU pharmaceutical standards, it induces active immunity that protects individuals of all ages against poliomyelitis.

GNH USA supplies Imovax Polio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance, cold‑chain logistics and regulatory compliance for global distribution across multiple continents.

Imovax Polio is an inactivated poliovirus vaccine used to prevent poliomyelitis, the disease caused by poliovirus infection. - Primary immunization: provides protective immunity in infants and young children as part of the routine childhood vaccination schedule. - Booster immunization: restores waning immunity in individuals previously vaccinated, extending protection into adulthood. - Travel protection: offers immunity for travelers to regions where poliovirus remains endemic or where outbreaks occur.

Imovax Polio may be associated with local and systemic reactions following injection. Common Side Effects: - Pain at injection site: mild to moderate discomfort where the vaccine is administered. - Redness: localized erythema around the injection area. - Fever: low‑grade temperature rise within 24‑48 hours. - Headache: mild headache reported after vaccination. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder characterized by muscle weakness. - Seizures: infrequent occurrence, especially in children with high fever.

Before administering Imovax Polio, certain precautions should be observed to ensure safety and optimal immunogenic response. - Allergy assessment: avoid use in individuals with known hypersensitivity to any vaccine component. - Immunocompromised patients: evaluate risk, although the inactivated vaccine is generally safe for this population. - Pregnancy considerations: administer only if the potential benefit justifies the potential risk to the fetus. - Concomitant vaccines: may be given at separate sites, but avoid simultaneous administration with live vaccines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imovax Polio has limited drug interaction potential, but certain substances may affect its immunogenicity or safety. Major Interactions (Avoid): - Immunoglobulin therapy: may diminish the antibody response to the vaccine. - Blood products: concurrent administration can interfere with vaccine efficacy. Moderate Interactions (Monitor Closely): - Antipyretics: use of acetaminophen or ibuprofen may mask fever, a common post‑vaccination sign. - Live viral vaccines: schedule at least 4 weeks apart to avoid immune interference. - Corticosteroids: high‑dose therapy may reduce vaccine‑induced immunity.